Status:
COMPLETED
Tadalafil Plus Tamsulosin for Male LUTS and ED
Lead Sponsor:
University of Florence
Conditions:
Prostatic Hyperplasia, Benign
Lower Urinary Tract Symptoms
Eligibility:
MALE
40-80 years
Brief Summary
Metabolic Syndrome (MetS) is a complex epidemic disorder with an impact on both lower urinary tract symptoms (LUTS) and erectile dysfunction (ED). Combination therapy of daily tadalafil and tamsulosin...
Detailed Description
75 Consecutive men presenting with ED and LUTS suggestive of bladder prostatic obstruction were enrolled. Patients were divided into two groups according to MetS presence or absence. All subjects were...
Eligibility Criteria
Inclusion
- mild to severe ED (International Index of Erectile Function-Erectile Function-5 \<22)
- moderate to severe LUTS (International Prostate Symptom Score \>7)
Exclusion
- hypersensitivity to tadalafil or tamsulosin
- prostatic cancer or suspected with prostate-specific antigen (PSA) \>4 ng/mL
- bladder lithiasis
- previous prostatic surgery
- urinary tract infection
- neurogenic bladder
- finasteride or dutasteride use within 3 or 6 months respectively
- clinical history of urethral and/or proven bladder neck obstruction
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2018
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT04383093
Start Date
January 1 2017
End Date
January 1 2018
Last Update
May 11 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.